Caricamento...
Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
BACKGROUND: Twenty years after the onset of diabetes, up to 40% of patients develop diabetic nephropathy. Protease-activated receptor-1 (PAR-1) has recently been shown to aggravate the development of experimental diabetic nephropathy. PAR-1 deficient mice develop less albuminuria and glomerular lesi...
Salvato in:
| Pubblicato in: | Oncotarget |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Impact Journals LLC
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5955164/ https://ncbi.nlm.nih.gov/pubmed/29774092 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25069 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|